Vaiomer Overview
- Year Founded
-
2011

- Status
-
Private
- Employees
-
11

- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$546K
- Investors
-
2
Vaiomer General Information
Description
Developer of microbiome biotechnology designed to offer biomarker identification services. The company's platform contributes to the discovery of innovative tools, biomarkers, and therapeutic targets related to tissue microbiome that help to establish early prognosis and therapies for numerous diseases such as cardiometabolic diseases, obesity, diabetes, liver fibrosis, cirrhosis, cardiac failure, neurodegenerative disorders, and infectious diseases, enabling doctors to identify bacterial community profiles.
Contact Information
Website
www.vaiomer.comCorporate Office
- 516 Rue Pierre et Marie Curie
- 31670 Labege
- France
Corporate Office
- 516 Rue Pierre et Marie Curie
- 31670 Labege
- France
Vaiomer Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Grant | 04-Apr-2019 | $546K | Completed | Generating Revenue | ||
2. Accelerator/Incubator | 20-Feb-2013 | Completed | Generating Revenue | |||
1. Accelerator/Incubator | 15-Feb-2013 | Completed | Generating Revenue |
Vaiomer Comparisons
Industry
Financing
Details
Vaiomer Competitors (49)
One of Vaiomer’s 49 competitors is Xalud Therapeutics, a Venture Capital-Backed company based in New York, NY.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Xalud Therapeutics | Venture Capital-Backed | New York, NY | ||||
Voyager Therapeutics | Corporation | Lexington, MA | ||||
Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
SynDevRx | Venture Capital-Backed | Cambridge, MA | ||||
Cornerstone Pharmaceuticals | Venture Capital-Backed | Cranbury, NJ |
Vaiomer Patents
Vaiomer Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3006625-A1 | Polydextrose for the prevention and/or treatment of heart failure | Active | 30-Nov-2015 | ||
CA-3006625-C | Polydextrose for the prevention and/or treatment of heart failure | Active | 30-Nov-2015 | ||
EP-3173085-A1 | Polydextrose for the prevention and/or treatment of heart failure | Inactive | 30-Nov-2015 | ||
EP-3383410-A1 | Polydextrose for the prevention and/or treatment of heart failure | Active | 30-Nov-2015 | ||
EP-3383410-B1 | Polydextrose for the prevention and/or treatment of heart failure | Active | 30-Nov-2015 | A61K31/715 |
Vaiomer Signals
Vaiomer Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Horizon 2020 | Government | |||
Nubbo | Accelerator/Incubator | Minority |
Vaiomer FAQs
-
When was Vaiomer founded?
Vaiomer was founded in 2011.
-
Where is Vaiomer headquartered?
Vaiomer is headquartered in Labege, France.
-
What is the size of Vaiomer?
Vaiomer has 11 total employees.
-
What industry is Vaiomer in?
Vaiomer’s primary industry is Biotechnology.
-
Is Vaiomer a private or public company?
Vaiomer is a Private company.
-
What is Vaiomer’s current revenue?
The current revenue for Vaiomer is
. -
How much funding has Vaiomer raised over time?
Vaiomer has raised $67.2K.
-
Who are Vaiomer’s investors?
Horizon 2020 and Nubbo have invested in Vaiomer.
-
Who are Vaiomer’s competitors?
Xalud Therapeutics, Voyager Therapeutics, Intellia Therapeutics, SynDevRx, and Cornerstone Pharmaceuticals are some of the 49 competitors of Vaiomer.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »